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Identification of Markers Associated With Development of Stroke in
“Clinically Low-Risk” Atrial Fibrillation Patients
Seung Yong Shin, MD, PhD;* Sang-Jin Han, MD;* Jin-Seok Kim, MD, PhD; Sung Il Im, MD, PhD; Jaemin Shim, MD, PhD; Jinhee Ahn, MD;
Eun Mi Lee, MD, PhD; Yae Min Park, MD; Jun Hyung Kim, MD; Gregory Y. H. Lip, MD, PhD;† Hong Euy Lim, MD, PhD†
Background-—Stroke and thromboembolic events may still occur in “clinically low-risk” atrial fibrillation (AF) patients as
categorized by CHA2DS2-VASc score. Our aim was to assess the proportion of “clinically low-risk” patients using a nongender
CHA2DS2-VASc (ie, CHA2DS2-VA) score of 0 to 1 among patients who experienced AF-associated stroke and to identify markers
associated with stroke in “clinically low-risk” patients.
Methods and Results-—We retrospectively recruited nonvalvular AF patients who experienced embolic stroke between 2013 and
2016 from 9 institutes in Korea. AF patients with CHA2DS2-VA score of 0 to 1 at the time of stroke were analyzed and compared
with “clinically low-risk” AF patients without stroke. A total of 3033 subjects with AF-associated stroke were recruited. Of these,
583 patients (19.2%) had CHA2DS2-VA score of 0 to 1. On multivariate analysis, age (≥60 years), N-terminal pro B-type natriuretic
peptide (≥300 pg/mL), creatinine clearance (<50 mL/min), and left atrial dimension (≥45 mm) were independently associated
with stroke. With the combined application of these 4 factors (collectively, ABCD score) to the “clinically low-risk” patients, the c-
index was 0.858 (95% CI 0.838–0.877; P<0.001).
Conclusions-—The present study suggests a new insight into how additional use of markers can further refine stroke risk
differentiation among AF patients initially classified as “clinically low-risk.”
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03147911. ( J Am Heart Assoc. 2019;8:
e012697. DOI: 10.1161/JAHA.119.012697.)
Key Words: ABCD score • atrial fibrillation • risk score • risk stratification • stroke, ischemic
P atients with atrial fibrillation (AF) have a 5-fold increasedrisk of stroke compared with matched individuals without
AF, and strokes associated with AF are more likely to be fatal
and disabling.1 Effective stroke prevention requires oral
anticoagulation (OAC),2 but this should be counterbalanced
by the potential risk of OAC-related bleeding events.1 As a
consequence, decision-making on whether OAC therapy
should be prescribed requires careful risk stratification.3
The CHA2DS2-VASc score is now used in many guidelines
for risk stratification and has a good performance in
identifying nonvalvular AF patients at low stroke risk.4
Nevertheless, stroke and thromboembolic events still occur
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in such “low-risk” AF patients as categorized by the CHA2DS2-
VASc score.3,5 Recently, the introduction of the non-vitamin K
oral anticoagulants (NOACs) has changed the landscape for
stroke prevention in AF, although regional differences are
apparent.6 The availability of NOAC has shifted the stroke
treatment threshold down to 0.9 event per 100-person
years; indeed, NOACs can be considered even for AF patients
with a nongender CHA2DS2-VASc score of 1.
7,8
The incidence of stroke among AF patients, especially in a
CHA2DS2-VASc score of 0 or 1, varies among different cohort
populations.5 Previous studies have suggested that the
application of a modified CHA2DS2-VASc score might be
more appropriate for stroke prevention in Asian popula-
tions.9,10 In addition, the influence of female sex (the Sc
criterion in CHA2DS2-VASc) on stroke risk in “low-risk” AF
patients is debatable because female sex may be a risk
modifier rather than a risk factor.11,12 In such low-risk
patients, use of the CHA2DS2-VA score (ie, female sex is
excluded, or nongender CHA2DS2-VASc score) would suffice
for risk stratification of such AF patients.12
Given that stroke events still occur in nonvalvular AF patients
who are considered clinically “low risk” with a CHA2DS2-VA
score of 0 or 1, further refinement of stroke risk stratification
would be helpful in identifying those AF patients who may or
may not get benefit from OAC therapy. Biomarkers have been
proposed to be useful for this purpose.13
Our aim was to assess the proportion of embolic stroke in
“low-risk” AF patients using a nongender CHA2DS2-VASc
score (ie, CHA2DS2-VA) of 0 to 1 and to identify markers
associated with stroke. Second, we used these data to derive
a novel risk stratification schema that includes biomarkers,
for refining stroke risk stratification among this “low-risk”
cohort.
Methods
Study Population and Design
This study is composed of 2 separate cohorts. First, we
retrospectively reviewed data of nonvalvular AF patients with
cardioembolic stroke between January 2013 and December
2016 from the nationwide stroke registry including 9
institutes in Korea. Of these, consecutive patients with a
CHA2DS2-VA score of 0 or 1 at the time of stroke event were
enrolled. Second, we defined a control group as subjects who
were matched by the nearest-neighbor method with type of
AF and CHA2DS2-VASc score among nonvalvular AF patients
without stroke from a consortium AF registry from 3 Korea
University Hospitals from 2015 to 2016.14
The CHA2DS2-VA score was calculated by adding 2 points
for age ≥75 years old and prior stroke or transient ischemic
attack, and 1 point for congestive heart failure (or left
ventricular ejection fraction ≤40%), hypertension, age 65 to
74 years, diabetes mellitus, and vascular disease (prior
myocardial infarction, peripheral artery disease or aortic
plaque) with a maximum 8 points.12,15
Medical records of all subjects were comprehensively
reviewed for demographic data, cardiovascular risk factors,
parameters of transthoracic echocardiography, and laboratory
data (complete blood counts, red blood cell distribution width,
NT-proBNP [N-terminal pro B-type natriuretic peptide], blood
urea nitrogen, creatinine, uric acid, and low-density choles-
terol). Left ventricular ejection fraction was calculated using
Simpson’s biplane method and dimension of the left atrium
(LA) was measured using M-mode of transthoracic echocar-
diography.
This study was conducted with approval of the Institutional
Review Board at each institution. The authors declare that all
supporting data are available within the article. The board
waived the need for patient consent because of the
retrospective, cross-sectional analysis design of the present
study. All procedures performed in the present study involving
human participants were in accordance with the ethical
standards of the institutional and/or national research
committee. This study was registered with ClinicalTrials.gov,
unique identifier NCT03147911.
AF Diagnosis and Cardioembolic Stroke
Diagnosis of AF was made on ECG showing the typical pattern
of AF with >30 s AF episode duration. AF was defined as
paroxysmal AF if its duration was <7 days and persistent AF if
its duration was ≥7 days. Nonvalvular AF was defined as the
absence of mitral stenosis (>mild) and prosthetic mechanical
mitral valve. Diagnosis of cardioembolic stroke was confirmed
by the neurologists of each institute according to TOAST (Trial
of Org 10172 in Acute Stroke Treatment) criteria.16
Clinical Perspective
What Is New?
• Among patients who had been classified as low risk by the
CHA2DS2-VASc scheme, the characteristics of patients who
experienced ischemic stroke were investigated.
What Are the Clinical Implications?
• Considering the improved risk–benefit ratio of non-vitamin K
oral anticoagulants, an updated or adjuvant scheme should
be required in order to identify patients who are at a truly
low risk for stroke.
• Although theABCD (age [≥60years],NT-proBNP (N-terminal pro
B-type natriuretic peptide) [≥300 pg/mL], creatinine clearance
[<50 mL/min], and left atrial dimension [≥45 mm]) scheme
was derived from the retrospective, cross-sectional assess-
ment, it is worth examining in a prospective way.
DOI: 10.1161/JAHA.119.012697 Journal of the American Heart Association 2






















Normally distributed continuous variables were expressed as
mean and SD, and categorical data were expressed as
numbers and percentages. Nonparametrically distributed data
were reported as median values with interquartile ranges. For
comparison across groups, continuous variables were com-
pared using the Student t test or analysis of variance, as
appropriate, and categorical variables were analyzed using the
v2 test or Fisher exact test, as appropriate. Univariate logistic
regression analysis was performed to identify the variables
that were significantly related to stroke event. A multivariate
logistic regression model was used to investigate the
independent risk factors of stroke events. Variables that
showed P value of <0.1 from the univariate logistic regression
model were entered into the multivariate regression models.
To assess the performance of the proposed risk differentiation
scheme, receiver operating characteristic analysis was per-
formed and the result of the receiver operating characteristic
analysis was internally validated and calibrated using the
bootstrapping technique to correct bias of the model. To
compare the performance of different models, 2 receiver
operating characteristic curves were compared according to
the method as described by DeLong et al.17 In order to
quantitatively compare the ability to differentiate patients at
risk according to each scheme, the integrated discrimination
improvement and the net reclassification index (NRI) with a
category-free option were calculated.18 A P value of <0.05
was considered statistically significant. All statistical analyses
were performed by R version 3.2.1 (Foundation for Statistical
Computing, Vienna, Austria) and STATA version 13.0 (Stata
Corp, College Station, TX).
Results
A total of 3033 nonvalvular AF subjects with cardioembolic
stroke were recruited. In Table 1, 583 patients (19.2%) had a
CHA2DS2-VA score of 0 or 1 (198 patients [6.5%] in CHA2DS2-
VA score of 0, 385 patients [12.7%] in CHA2DS2-VA score of
1). As a control group, 598 subjects were extracted from the
nonvalvular AF registry consortium by nearest-neighbor
propensity matching. Stroke patients were significantly older,
with a female predominance, and had significantly lower
estimated creatinine clearance rate (CCr), larger LA dimen-
sion, and higher uric acid and NT-proBNP levels, as compared
with controls. When compared with the stroke group, control
subjects had a significantly higher prevalence of hypertension
and diabetes mellitus. There was no significant difference in
mean CHA2DS2-VA score between the 2 groups.
Based on the CHA2DS2-VASc score, 462 patients with
stroke (15.2%) had a CHA2DS2-VASc score of 0 or 1 (136
patients [4.5%] in CHA2DS2-VASc score of 0, 326 patients
[10.7%] in a CHA2DS2-VASc score of 1). Baseline character-
istics of subjects with CHA2DS2-VASc score of 0 or 1 are
described in Table 2.
Biomarkers Associated With Stroke
On univariate analysis, older age (≥60 years), being female,
hypertension, diabetes mellitus, LA dimension (≥45 mm), red
blood cell distribution width, CCr (<50 mL/min), uric acid
(>7 mg/dL), and NT-proBNP (≥300 pg/mL) were significantly
associated with stroke events (Table 3). Type of AF and left
ventricular ejection fraction were not significantly related with
stroke events. Eleven variables (older age, being female,
hypertension, diabetes mellitus, vascular disease, CHA2DS2-
VA score, LA dimension [≥45 mm], red blood cell distribution
width, CCr [<50 mL/min], uric acid [>7 mg/dL], and NT-
proBNP [≥300 pg/mL]) were included in the multivariate
logistic regression analysis.
On the multivariate regression model, age (≥60), NT-
proBNP (≥300 pg/mL), CCr (<50 mL/min), and LA dimension
(≥45 mm) were independently associated with stroke events.
These were used to derive a simple score, ABCD (Age, NT-
proBNP, CCr, and Dimension of the LA) score, based on the
independent associated factors for stroke events. The b
coefficient of each independent risk factor was assigned to a
score number and each selected factor was assigned 1 point.
Performance of ABCD Score in Differentiating in
“Clinically Low-Risk” Patients
The distribution of the CHA2DS2-VA score of 0 to 1 patients by
the ABCD score is shown in Figure 1. There was a significant
increase in stroke events according to increase in the ABCD
score points (P<0.001) in patients with a CHA2DS2-VA score of
0 to 1 and those with a CHA2DS2-VASc score of 0 to 1.
Figure 2 shows the area under the resulting c-indexes
(based on receiver operating characteristic curves) of the
ABCD score. The c-index of the ABCD score was 0.858 (95%
CI 0.838–0.877; P<0.001) in patients with a CHA2DS2-VA
score of 0 to 1, and 0.850 (95% CI 0.827–0.873; P<0.001) in
those with a CHA2DS2-VASc score of 0 to 1. The internally
validated c-index of ABCD score was 0.780 (95% CI 0.752–
0.808) using a bootstrapping procedure. With Hosmer–
Lemeshow test, model calibration of ABCD score showed
good agreements between observed stroke event and
expected stroke event (P=0.077, Figure 3).
ABCD Score Versus CHA2DS2-VA or CHA2DS2-
VASc Score
The c-indexes of the CHA2DS2-VA and CHA2DS2-VASc score
were 0.527 (95% CI 0.499–0.554; P<0.001) and 0.548
DOI: 10.1161/JAHA.119.012697 Journal of the American Heart Association 3
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(0.519–0.577; P<0.001), respectively (Figure 2). Corrected c-
indexes from 1000 bootstrap samples for ABCD, CHA2DS2-
VA, and CHA2DS2-VASc score were 0.870 (95% CI 0.848–
0.891), 0.632 (95% CI 0.606–0.656), and 0.649 (95% CI
0.621–0.677), respectively. The c-index of the ABCD score
was higher than those of the CHA2DS2-VA or CHA2DS2-VASc
score (Table 4; DeLong test z=21.53; P<0.001, z=19.08;
P<0.001, respectively).
The integrated discrimination improvement of the ABCD
score was significantly improved as compared with
CHA2DS2-VA and CHA2DS2-VASc score (Table 4; integrated
discrimination improvement=0.339; P<0.001, integrated
discrimination improvement=0.334; P<0.001, respectively).
Significant NRIs were present with the ABCD score as
compared with CHA2DS2-VA and CHA2DS2-VASc score,
respectively (Table 4).
Discussion
The present study has several noteworthy findings: (1) among
AF patients who developed a stroke, 19.2% had a CHA2DS2-
VA score of 0 or 1; (2) clinical, biomarker, and imaging factors
(ie, age [≥60], NT-proBNP [≥300 pg/mL], CCr [<50 mL/min],
dimension of LA [≥45 mm], incorporated in the ABCD score)
were independently associated with stroke events even in AF
Table 1. Baseline Characteristics of Subjects
Stroke (N=583) Control (N=598) P Value
Age, y 60.98.4 52.39.5 <0.001
Age ≥65 y 176 (30.2%) 41 (6.9%) <0.001
Female sex 183 (31.4%) 146 (24.4%) 0.009
Persistent AF 318 (55.1%) 306 (51.2%) 0.195
CHF 27 (4.6%) 41 (6.9%) 0.129
HTN 158 (27.1%) 228 (38.1%) <0.001
DM 20 (3.4%) 41 (6.9%) 0.011
Vascular disease 4 (0.7%) 12 (2.0%) 0.087
CHA2DS2-VA score 0.065
0 198 (34.0%) 235 (39.3%)
1 385 (66.0%) 363 (60.7%)
Sex with CHA2DS2-VA score
Male with 0 136 (23.3%) 179 (29.9%) 0.012
Male with 1 264 (45.3%) 273 (45.7%) 0.945
Female with 0 62 (10.6%) 56 (9.4%) 0.528
Female with 1 121 (20.8%) 90 (15.1%) 0.013
Male with 0 or 1 and
female with 0
462 (79.2%) 508 (84.9%) 0.013
LVEF, % 60.0 (10.2) 62.5 (5.0) 0.144
LA dimension, mL 43.1 (9.0) 39.5 (7.5) <0.001
Hb, g/dL 14.2 (2.2) 14.1 (2.6) 0.703
RDW, % 13.2 (1.2) 13.1 (0.9) 0.142
LDL, mg/dL 101.733.4 104.628.7 0.149
CCr, mL/min 78.2 (31.6) 98.9 (32.6) <0.001
Uric acid, mg/mL 5.3 (2.2) 4.8 (2.2) <0.001
NT-proBNP pg/mL 524.5 (608.5) 80.3 (172.9) <0.001
Data are presented as meanSD or median (interquartile range). AF indicates atrial
fibrillation; CCr, creatinine clearance rate; CHA2DS2-VA, congestive heart failure,
hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74 years; CHF, congestive heart failure; DM, diabetes
mellitus; vascular disease, peripheral artery disease, myocardial infarction or aortic
plaque; Hb, hemoglobin; HTN, hypertension; LA, left atrium; LDL, low-density lipoprotein;
LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic
peptide; RDW, red blood cell distribution width.
Table 2. Baseline Characteristics of Subjects With CHA2DS2-
VASc Score of 0 or 1
Stroke (N=462) Control (N=508) P Value
Age, y 59.88.3 51.39.6 <0.001
Age ≥65 y 114 (24.7%) 28 (5.5%) <0.001
Female sex 62 (13.4%) 56 (11.0%) 0.297
Persistent AF 246 (53.7%) 264 (52.0%) 0.633
CHF 18 (3.9%) 30 (5.9%) 0.196
HTN 112 (24.2%) 173 (34.1%) 0.001
DM 17 (3.7%) 30 (5.9%) 0.144
Vascular disease 3 (0.6%) 12 (2.4%) 0.058
CHA2DS2-VASc score 0.317
0 136 (29.4%) 179 (35.2%)
1 326 (70.6%) 329 (64.8%)
Sex with CHA2DS2-VASc score
Male with 0 136 (29.4%) 179 (35.2%) 0.063
Male with 1 264 (57.1%) 273 (53.7%) 0.317
Female with 0 62 (13.4%) 56 (11.0%) 0.297
LVEF, % 59.0 (11.0) 62.5 (7.5) 0.123
LA dimension, mL 43.1 (9.0) 39.5 (7.5) <0.001
Hb, g/dL 14.4 (2.2) 14.4 (2.6) 0.864
RDW, % 13.2 (1.2) 13.1 (0.9) 0.096
LDL, mg/dL 102.0 (44.5) 100.0 (39.0) 0.239
CCr, mL/min 80.8 (31.9) 100.0 (32.3) <0.001
Uric acid, mg/mL 5.6 (2.1) 5.1 (2.2) <0.001
NT-proBNP pg/mL 480.0 (574.0) 76.8 (171.6) <0.001
Data are presented as meanSD or median (interquartile range). AF indicates atrial
fibrillation; CCr, creatinine clearance rate; CHA2DS2-VASc, congestive heart failure,
hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74 years; CHF, congestive heart failure; DM, diabetes
mellitus; vascular disease, peripheral artery disease, myocardial infarction or aortic
plaque; Hb, hemoglobin; HTN, hypertension; LA, left atrium; LDL, low-density lipoprotein;
LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic
peptide; RDW, red blood cell distribution width.
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patients with a CHA2DS2-VA score of 0 to 1 and CHA2DS2-
VASc score of 0 to 1; and (3) the ABCD score was significantly
superior to those of the CHA2DS2-VA or CHA2DS2-VASc score
in differentiating “truly low-risk” patients.
The present study provides new insights into how addition
of biomarkers can further refine stroke risk stratification
among AF patients initially defined as “clinically low risk”
based on the CHA2DS2-VA criteria. Major guidelines have
Table 3. Univariate and Multivariate Logistic Regression Analysis for Factors Associated With Stroke in Patients With AF
CHA2DS2-VA Score of 0 or 1
Univariate Analysis Multivariate Analysis
Pt.ß OR (95% CI) P Value ß OR (95% CI) P Value
Age ≥60 y 1.75 5.78 (4.5–7.45) <0.001 1.623 5.06 (3.38–7.56) <0.001 1
Female sex 0.348 1.42 (1.10–1.83) 0.008 0.047 1.05 (0.69–1.59) 0.823
Persist AF 0.158 1.17 (0.93–1.47) 0.176
CHF 0.416 0.66 (0.40–1.09) 0.103
HTN 0.505 0.60 (0.47–0.77) <0.001 0.197 0.82 (0.49–1.37) 0.448
DM 0.729 0.48 (0.28–0.83) 0.009 0.360 0.70 (0.28–1.75) 0.442
Vascular disease 1.087 0.34 (0.11–1.05) 0.061 0.564 0.57 (0.11–2.89) 0.496
CHA2DS2-VA score 0.230 1.26 (0.98–1.60) 0.057 0.375 0.69 (0.41–1.16) 0.163
LVEF, % 0.010 0.99 (0.98–1.0) 0.138
LA diameter ≥45 mm 1.312 3.71 (2.83–4.87) <0.001 1.39 4.01 (2.70–5.97) <0.001 1
RDW 0.172 1.19 (1.07–1.32) 0.001 0.035 0.97 (0.86–1.09) 0.561
LDL, mg/dL 0.003 1.00 (0.99–1.00) 0.143
CCr (<50 mL/min) 2.483 11.98 (5.13–27.97) <0.001 1.933 6.91 (2.06–23.22) 0.002 1
Uric acid (>7 mg/dL) 0.658 1.93 (1.32–2.83) 0.008 0.186 1.20 (0.68–2.14) 0.527
NT-proBNP (≥300 pg/mL) 2.759 15.78 (11.81–21.08) <0.001 2.005 7.42 (5.15–10.70) <0.001 1
AF indicates atrial fibrillation; CCr, creatinine clearance rate; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74; CHF, congestive heart failure; DM, diabetes mellitus; vascular disease, peripheral artery disease, myocardial infarction or aortic plaque; HTN, hypertension;
LA, left atrium; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; OR, odds ratio; Pt, point; RDW, red blood cell
distribution width.
Figure 1. Distribution of AF patients with stroke event according to the ABCD score. A, Distribution of ABCD score in patients with CHA2DS2-
VA score 0 or 1 is shown. B, Distribution of ABCD score in patients with CHA2DS2-VASc score 0 or 1 is shown. ABCD indicates age, NT-proBNP,
CCr, and dimension of the LA; AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior
stroke or transient ischemic attack, vascular disease, and age 65 to 74; and CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75,
diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category; CCr, creatinine clearance
rate; LA, left atrium; NT-proBNP, N-terminal pro B-type natriuretic peptide.
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recommended OAC treatment for prevention of thromboem-
bolic events in patients with AF and CHA2DS2-VA and
CHA2DS2-VASc score of ≥2.
19,20 Nevertheless, AF patients
with 1 nongender CHA2DS2-VASc risk factor still have an
elevated risk of stroke compared with patients with a
CHA2DS2-VASc score of 0 and the clinical benefit of OAC
may be positive in these patients.5,7 However, the risk
contribution of each component of the CHA2DS2-VASc score
is not homogeneous.21 As a consequence, decision-making
for OAC in patients with AF and a CHA2DS2-VASc score of 1
requires consideration of bleeding risk and an individual
weighing of stroke risk.19,21 In this regard, adjuvant risk
stratification using biomarkers may provide additional infor-
mation to aid OAC treatment decision-making in these
patients.19
The incidence of stroke in risk stratification scheme
according to the CHA2DS2-VASc score also varies among
different cohorts because of the characteristics of subjects,
such as the proportions of different ethnicity, prevalence of
chronic kidney disease, degree of LA remodeling, etc.10
Furthermore, the impact of female sex on stroke among low-
risk patients with AF is controversial,11,12,22,23 and 1 recent
study revealed that female sex was a “risk modifier” for stroke
rather than a risk factor.12 Of note, the incidence of stroke in
Figure 2. Receiver operating characteristic curve of the ABCD
score for identifying a population with a truly low risk of stroke in
AF patients. C-index of ABCD score was 0.858 (95% CI 0.838–
0.877) and its risk stratification in low-risk group was superior to
that of CHA2DS2-VA or CHA2DS2-VASc score. ABCD indicates
age, NT-proBNP, CCr, and dimension of the LA; AF, atrial
fibrillation; CHA2DS2-VA, congestive heart failure, hypertension,
age ≥75 years, diabetes mellitus, prior stroke or transient
ischemic attack, vascular disease, and age 65 to 74 years;
AUC, area under the curve; CHA2DS2-VASc, congestive heart
failure, hypertension, age ≥75, diabetes mellitus, prior stroke or
transient ischemic attack, vascular disease, age 65 to 74 years,
and sex category.
Figure 3. Calibration of ABCD score. ABCD score categories
were defined as low risk (score=0), moderate risk (score 1, 2), and
high risk (score 3, 4). There were no significant differences
between observed stroke event number (blue) and expected
stroke event number (red). ABCD indicates age, NT-proBNP, CCr,
and dimension of the LA; AF, atrial fibrillation; CHA2DS2-VA,
congestive heart failure, hypertension, age ≥75 years, diabetes
mellitus, prior stroke or transient ischemic attack, vascular
disease, and age 65 to 74 years; CCr, creatinine clearance rate;
LA, left atrium; NT-proBNP, N-terminal pro B-type natriuretic
peptide.
Table 4. C-Indexes, IDI, and NRI of the ABCD Score in Comparison With CHA2DS2-VA and CHA2DS2-VASc Score
C-Index 95% CI P Value z Statistics* P Value* IDI* P Value* NRI* P Value*
ABCD 0.858 0.838–0.877 <0.001
CHA2DS2-VA 0.527 0.499–0.554 <0.001 21.53 <0.001 0.339 <0.001 0.769 <0.001
CHA2DS2-VASc 0.548 0.519–0.577 <0.001 19.08 <0.001 0.334 <0.001 0.787 <0.001
ABCD indicates age ≥60 years, NT-proBNP ≥300 pg/mL, CCr <50 mL/min, and dimension of LA ≥45 mm; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years, diabetes
mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74 years; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or
transient ischemic attack, vascular disease, age 65 to 74 years, sex category; CCr, creatinine clearance rate; IDI, integrated discriminatory improvement; NRI, net reclassification index; NT-
proBNP, N-terminal pro B-type natriuretic peptide.
*For comparison with ABCD score.
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Asian people may be higher compared with the white
population, especially in patients with AF and a CHA2DS2-
VASc score of 0 in whom OAC therapy is not indicated.10,24
Therefore, identifying “truly low-risk” patients using an
adjuvant risk stratification scheme would be of clinical value
in patients with AF and a low-risk CHA2DS2-VA or CHA2DS2-
VASc profile (score of 0 or 1). Indeed, the approach to stroke
prevention in AF has moved towards the default being OAC
use unless the patient was deemed low risk, so relying on
clinical risk stratification alone has limitations. As shown in
this study, one fifth of patients with cardioembolic stroke
were defined as clinically “low risk” based on the CHA2DS2-VA
criteria, showing that further improvement in refining risk
stratification is still needed in this group. Biomarkers have
been proposed to have such a role.
Biomarkers (“biological markers”), whether blood, urine, or
imaging based, will always improve on stroke risk stratifica-
tion based on clinical factors.25 Nevertheless, the use of
multiple biomarkers has to be balanced against simplicity and
practicality (and costs) of decision-making for OAC use, for
stroke prevention in AF. In the present study, the ABCD score,
which includes 2 blood biomarkers (NT-proBNP, creatinine
clearance) and 1 imaging marker (LA dimension), showed
good discriminatory value in both AF patients with a
CHA2DS2-VA score of 0 to 1 or a CHA2DS2-VASc score of 0
to 1. Our results would suggest that the ABCD score can help
physicians discriminate patients who have a truly low risk
among AF patients with a CHA2DS2-VA or CHA2DS2-VASc
score of 0 to 1 and would not require OAC treatment.
Consistent with our study, previous reports have demon-
strated that elevated biomarkers such as NT-proBNP level, red
blood cell distribution width, and uric acid level were
significantly associated with stroke in patients with AF.26–28
In the present study, red blood cell distribution width, uric
acid levels (>7 mg/dL), and NT-proBNP level (≥300 pg/mL)
were positively associated with stroke events on univariate
analysis; however, only NT-proBNP level (≥300 pg/mL) was
an independent predictor for stroke on multivariate analysis.
Indeed, NT-proBNP levels have been positively associated
with the incidence of stroke.26,29
In the present study, CCr (<50 mL/min) was another
independent risk factor of stroke and this corresponds with
prior studies.30,31 Age is also a powerful driver of stroke risk in
AF,32 and also contributes 1 point to the ABCD score. Finally, LA
enlargement contributes to blood stasis into the LA, and
endothelial dysfunction of the LA may lead to thrombus
formation.33 LA enlargement may be a marker of atrial
cardiomyopathy, which may cause thromboembolic events
given atrial tissue abnormalities, such as fibrosis, endothelial
cell dysfunction, and myocyte apoptosis.33–35 Some studies
have also shown that a dilated LA (≥45 mm) is associated with
increased risk of stroke, consistent with our results.36,37
Limitations
Several limitations should be acknowledged. First, we were
unable to estimate the annual stroke rate based on the ABCD
score because of the retrospective nature and cross-sectional
design of the present study. Second, since our study included
only a Korean population, these results cannot be extrapo-
lated to subjects of other ethnicities. Third, although the
internal bootstrapping approach was conducted to supple-
ment the absence of an external validation cohort, further
studies on cohorts with different ethnicity will be needed to
validate the ABCD score.
Conclusions
The present study provides new insights into how addition of
biomarkers can further refine stroke risk stratification among
AF patients initially defined as clinically “low risk.” Almost one
fifth of AF patients initially defined as “low risk” based on
nongender clinical CHA2DS2-VASc criteria experienced
embolic stroke. The ABCD score that applies biomarkers
(NT-proBNP, creatinine clearance) and imaging (LA dimension)
can further refine stroke risk stratification in this “clinically
low-risk” patient group, and can help discriminate the AF
population who are a “truly low-risk” group.
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